Skip to content

Search

Showing results for "Childhood interstitial lung disease "

Clinical Epigenetics

Epigenomic research at The Kids explores the links between childhood disease and the molecular hallmarks of epigenetic control.

Elizabeth Wilkes

Liz Wilkes is a Noongar woman with family connections to the Wadjuk and Ballardong tribes. She has a background in nursing and a passion for Aboriginal health and community engagement.

START: Towards a diagnostic test for rheumatic fever

In this study we will use new methods to comprehensively test immune responses in blood samples from people with ARF (diagnosed using the Jones Criteria) and healthy volunteers at Royal Darwin and from Auckland Hospital, New Zealand, to find any unique signature that reliably identifies ARF.

Respiratory impedance in healthy unsedated South African infants: Effects of maternal smoking

Non-invasive techniques for measuring lung mechanics in infants are needed for a better understanding of lung growth and function...

The mechanism or mechanisms driving atopic asthma initiation: The infant respiratory microbiome moves to center stage

Although debate surrounding the mechanism or mechanisms governing this causal pathway remains intense, demonstration of the capacity of pretreatment...

Fragranced consumer products: effects on asthmatic Australians

Most asthmatics would prefer workplaces, healthcare facilities, and environments that are fragrance-free, which could help reduce adverse effects

A rapid semi-quantitative screening method to assess chemicals present in heated e-liquids and e-cigarette aerosols

Electronic cigarettes (e-cigarettes) lack regulatory status as therapeutic products in all jurisdictions worldwide. They are potentially unsafe consumer products, with significant evidence they pose a risk to human health. Therefore, developing rapid, economical test methods to assess the chemical composition of e-liquids in heated and unheated forms and the aerosols produced by e-cigarettes is crucial.

The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research

Alcohol pharmacotherapies pose unknown teratogenic risks in pregnancy and are therefore recommended to be avoided. This limits treatment options for pregnant individuals with alcohol use disorders (AUD). The information on the safety of these medications during pregnancy is uncertain, prompting a scoping review. The objective of this review was to investigate available information on the safety of alcohol pharmacotherapies in pregnancy.

The effects of acamprosate on maternal and neonatal outcomes in a mouse model of alcohol use disorders

Despite the teratogenic effects of alcohol, little is known about the safety of pharmacotherapies such as acamprosate for the treatment of alcohol use disorders in pregnancy. The aims of this study were to investigate, in a mouse model, the effects of maternally administered acamprosate on maternal and neonatal health, offspring neurodevelopment and behaviour, as well as examine whether acamprosate reduces the neurological harm associated with alcohol consumption in pregnancy.